Compare Moderna, Inc. (MRNA) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Moderna, Inc. trades at $136.54 (market cap $54.14B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $44.53. The key difference: Moderna, Inc. is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| MRNA | VNQI | |
|---|---|---|
Market Cap | $54.14B | — |
Sector | Health | — |
52-Week High | $174.38 | $50.76 |
52-Week Low | $22.36 | $43.26 |
Enterprise Value | $50.29B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
VNQI, the Vanguard Global ex-U.S. Real Estate ETF, trades at $44.95, down 0.71% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF focuses on international real estate across over 30 countries, offering a higher dividend yield than many peers but has shown lower total returns recently. Recent news highlights its price crossing below the 50-day moving average and comparisons with other real estate ETFs.
The outlook for VNQI is cautious due to bearish technical trends and underperformance versus U.S.-focused real estate ETFs. Opportunities include diversification benefits and attractive dividend yield, but risks involve global economic sensitivity and currency fluctuations. Investors should weigh international exposure against potential volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
